Company Overview
Snapshot
Founded in October 2018 by David Bassa, Cannamore Biotechs operates with 1–10 employees. The company is currently in the Pre-Funding stage and completed its acceleration program with BioSeedXL in March 2019.
Business overview
Cannamore Biotechs is a preclinical and clinical-stage research platform company focused on developing novel and improved cannabis-based treatment options. The company's core technology involves CBD-based solutions for conditions such as bronchiolitis obliterans, peripheral neuropathy, and inflammatory bowel diseases. Operating within the Health Tech & Life Sciences sector, Cannamore Biotechs targets the pharmaceutical and biotechnology industries globally, aiming to provide established medicines through clinical trials and collaboration.
Strategic signal
In September 2022, an interview with founder David Bassa highlighted Cannamore Biotechs' strategic focus on advancing medical cannabis-based therapies. This signals the company's commitment to leveraging biotech for safe and regulated treatments, emphasizing the need for collaboration with large pharmaceutical companies to further develop and commercialize its solutions. This indicates a strategic push towards partnerships and clinical validation to establish its CBD-based products in the market.
Log in to access full profile ›Company Intelligence Q&A
- What is Cannamore Biotechs' primary focus in drug development?
- Cannamore Biotechs is focused on developing CBD-based solutions for the treatment of bronchiolitis obliterans, peripheral neuropathy, and inflammatory bowel diseases.
- When was Cannamore Biotechs founded and by whom?
- Cannamore Biotechs was founded in October 2018 by David Bassa.
- What was a significant early milestone for Cannamore Biotechs?
- Cannamore Biotechs completed its acceleration program with BioSeedXL in March 2019, indicating an early strategic partnership and development phase.
- What is the company's current product development stage?
- Cannamore Biotechs is currently in the Clinical Trial stage with its products, focusing on advancing CBD-based solutions for conditions such as bronchiolitis obliterans, peripheral neuropathy, and inflammatory bowel diseases. The company aims to provide established medicines through clinical trials and collaboration with pharmaceutical and biotechnology industries.
- What is the strategic importance of medical cannabis to Cannamore Biotechs?
- In September 2022, founder David Bassa emphasized the potential of medical cannabis in providing safe and regulated treatments, highlighting the company's commitment to advancing these therapies through biotech and seeking collaboration with larger pharmaceutical companies.